Onconetix, Inc. Earnings Per Share Disclosure

Note 13 — Net Loss Per Share

 

Basic net loss per share is computed by dividing the net income or loss applicable to common shares by the weighted average number of common shares outstanding during the period. The weighted average number of shares of common stock outstanding includes pre-funded warrants because their exercise requires only nominal consideration for delivery of shares; it does not include any potentially dilutive securities or any unvested restricted shares of common stock. Certain restricted shares, although classified as issued and outstanding at December 31, 2024, are considered contingently returnable until the restrictions lapse and will not be included in the basic net loss per share calculation until the shares are vested. Unvested shares of the Company’s restricted stock do not contain non-forfeitable rights to dividends and dividend equivalents.

 

The two-class method is used to determine earnings per share based on participation rights of participating securities in any undistributed earnings. Each share of preferred stock that includes rights to participate in distributed earnings is considered a participating security and the Company uses the two-class method to calculate net income available to the Company’s common stockholders per common share — basic and diluted.

 

The following securities were excluded from the computation of diluted shares outstanding due to the losses incurred in the periods presented, as they would have had an anti-dilutive impact on the Company’s net loss:

 

		For the Years Ended December 31,
		2024				2023
Options to purchase shares of common stock			13,674				47,619
Warrants			1,175,333				197,492
Unvested shares of restricted stock			17,917				6,414
Common stock issuable upon conversion of Series A Preferred Stock			-				142,749
Common stock issuable upon conversion of Series C Redeemable Preferred Stock			776,589				-
Total			1,983,513				394,274